Next Article in Journal
LncRNAs as Chromatin Regulators in Cancer: From Molecular Function to Clinical Potential
Previous Article in Journal
Targeting Lysophosphatidic Acid in Cancer: The Issues in Moving from Bench to Bedside
Previous Article in Special Issue
PTEN and Gynecological Cancers
Open AccessReview

Revising PTEN in the Era of Immunotherapy: New Perspectives for an Old Story

1
Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Roma, Italy
2
Department of Medicine, University of Verona, 37134 Verona, Italy
3
Division of Gynecologic Oncology, Department of Woman and Child Health and Public Health, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Roma, Italy
4
Medical Oncology, Azienda Ospedaliera Universitaria Integrata, 37134 Verona, Italy
5
Medical Oncology, Università Cattolica Del Sacro Cuore, 00168 Roma, Italy
*
Author to whom correspondence should be addressed.
G.P. and C.C. share the first co-authorship.
E.B. and G.T. share the last co-authorship.
Cancers 2019, 11(10), 1525; https://doi.org/10.3390/cancers11101525
Received: 31 July 2019 / Revised: 17 September 2019 / Accepted: 30 September 2019 / Published: 10 October 2019
(This article belongs to the Special Issue PTEN: A Multifaceted Tumor Suppressor)
Immunotherapy has emerged as the new therapeutic frontier of cancer treatment, showing enormous survival benefits in multiple tumor diseases. Although undeniable success has been observed in clinical trials, not all patients respond to treatment. Different concurrent conditions can attenuate or completely abrogate the usefulness of immunotherapy due to the activation of several escape mechanisms. Indeed, the tumor microenvironment has an almost full immunosuppressive profile, creating an obstacle to therapeutic treatment. Phosphatase and tensin homolog deleted on chromosome 10 (PTEN) governs a plethora of cellular processes, including maintenance of genomic stability, cell survival/apoptosis, migration, and metabolism. The repertoire of PTEN functions has recently been expanded to include regulation of the tumor microenvironment and immune system, leading to a drastic reevaluation of the canonical paradigm of PTEN action with new potential implications for immunotherapy-based approaches. Understanding the implication of PTEN in cancer immunoediting and immune evasion is crucial to develop new cancer intervention strategies. Recent evidence has shown a double context-dependent role of PTEN in anticancer immunity. Here we summarize the current knowledge of PTEN’s role at a crossroads between tumor and immune compartments, highlighting the most recent findings that are likely to change future clinical practice. View Full-Text
Keywords: PTEN; immunotherapy; regulatory T cells; immunosuppression PTEN; immunotherapy; regulatory T cells; immunosuppression
Show Figures

Figure 1

MDPI and ACS Style

Piro, G.; Carbone, C.; Carbognin, L.; Pilotto, S.; Ciccarese, C.; Iacovelli, R.; Milella, M.; Bria, E.; Tortora, G. Revising PTEN in the Era of Immunotherapy: New Perspectives for an Old Story. Cancers 2019, 11, 1525.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop